Home Featured Page 229

Featured

Latest

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...

MindMed CMO to Chair Digital Biomarkers Summit

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial...

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson...

More Evidence of the Chemical Compound Variability in Magic Mushrooms

PTSF82 – Wonderland Miami, with Patrick Moher of Microdose

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy...

Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in...

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Open-label study of COMP360 psilocybin therapy for depression in cancer patients...

EDITOR PICKS

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the...

MindMed CMO to Chair Digital Biomarkers Summit

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial...

Psychedelic Bulletin: Small Pharma Secures Fast-Track Designation in UK; Boris Johnson...

More Evidence of the Chemical Compound Variability in Magic Mushrooms

PTSF82 – Wonderland Miami, with Patrick Moher of Microdose

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy...

Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in...

Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product

Open-label study of COMP360 psilocybin therapy for depression in cancer patients...

EDITOR PICKS

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY